485P A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study

Abstract

cohort, separately. TMB was defined as the number of somatic nonsynonymous somatic mutations per megabase in the coding region of WES. The tumor-related immune cells infiltration level difference between mutant and wildtype tumors were inferred using TIMER 2.0 (Wilcoxon test). The association between MUC16 mutation states and the efficacy of ICIs was performed in melanoma patients from Miao2018 pan-cancer ICIs treatment cohort.Results: In total, the alteration frequency of MUC16 gene in COAD was 28% (148/526) in TCGA cohort and 27% (18/66) in Chinese cohort. In TCGA cohort, the expression of MUC16 of COAD tumor tissues was significantly higher than adjacent normal tissues (p<0.001). The level of infiltration of CD8+ T cell, B cell, T cell regulatory (Tregs) and NK cell were all significantly increased in mutated tumors compared with wild-type tumors (p < 0.05). The mutant tumors with significantly higher inferred M1 macrophages than wildtype (p¼0.0014), but not in M2 macrophages. In Chinese cohort, the TMB level was higher in mutant group compared to wild-type group (median TMB, mut vs wt ¼ 18.26 vs 2.72 Mut/Mb, p < 0.0001). The percentage of microsatellite instability-high (MSI-H) in MUC16 mutant tumors was 50.00%, while 8.33% in wildtype tumors (Fisher's exact test, p ¼ 0.0005). The overall survival (OS) of MUC16 mutation group (n¼43) were significantly longer than wild-type group (n¼108) (median OS, mutation vs wild-type ¼ 20.33 vs 9.77 months; HR 0.59[95% CI 0.37-0.92]; p ¼ 0.019). Conclusions:The MUC16 mutation COAD tumors had highly TMB levels and infiltrating lymphocytes, which may serve as a potential biomarker to guide ICB therapy in COAD.